The complaint filed by Bronstein, Gewirtz & Grossman, LLC contends that Fractyl Health misled shareholders about the performance of its Revita system. According to the filing, the company failed to disclose that the technology was less effective than claimed and that operational failures at clinical sites within the REMAIN-1 Midpoint Cohort compromised the integrity of its results. Consequently, the lawsuit argues that the company’s public statements concerning its regulatory and commercial prospects were materially inaccurate.
In section Releases
Fractyl Health Faces Class Action Over Alleged Misleading Clinical Data
Investors who purchased Fractyl Health securities between January 13, 2025, and January 29, 2026, are being urged to join a newly filed class action lawsuit. The litigation targets the company and specific officers for allegedly disseminating false information regarding the efficacy of their Revita medical technology.
Shareholders who suffered financial losses have until October 20, 2026, to apply to the court to serve as lead plaintiff. While the firm operates on a contingency fee basis, investors do not need to serve as lead plaintiff to participate in any potential recovery. Those interested in reviewing the complaint or obtaining further information may contact Peretz Bronstein or Nathan Miller at 917-590-0911.
Comments (0)
No comments yet. Be the first!